Top ophthalmology stories of July

The most-read ophthalmology articles on Healio.com/OSN in July included journal summaries and FDA news.

Here are the top five most-viewed stories from the month:

How to look at private equity investment in physician groups: Eye care

In this second of six articles from the lawyers from Epstein Becker & Green and the analysts from Provident Healthcare Partners, LLC, Steven Grassa and Anjana D. Patel, Esq., delve into the hot sector of eye care, explaining how private equity investment is growing in this field. Read more here .

FDA accepts biologics license application for voretigene neparvovec

An investigational gene therapy candidate for vision loss due to biallelic RPE65-mediated inherited retinal disease (IRD), voretigene neparvovec, which has the proposed trade name of Luxturna, could be both the first gene therapy for a genetic disease in the United States and the first pharmacologic treatment for IRD. Read more here.

Latest LASIK platforms boost patient-reported outcomes

A meta-analysis of FDA patient-reported outcomes showed significant improvement in night vision and driving after LASIK with three of the latest FDA-approved laser platforms. Patient satisfaction was high, and dry eye was mild and transient. Read more here, including peer perspective from Jorge L. Alió, MD, PhD.

NEI highlights advancements for Dry Eye Awareness Month

Recent advancements in dry eye disease research are leading to developments in long-term therapies, according to the National Eye Institute. Read more here.

Diabetes-related retinal ganglion cell loss starts early

Retinal ganglion cell loss due to type 1 diabetes begins in early childhood and is detectable by OCT before any sign of diabetic retinopathy occurs, according to a study. Read more here.

The most-read ophthalmology articles on Healio.com/OSN in July included journal summaries and FDA news.

Here are the top five most-viewed stories from the month:

How to look at private equity investment in physician groups: Eye care

In this second of six articles from the lawyers from Epstein Becker & Green and the analysts from Provident Healthcare Partners, LLC, Steven Grassa and Anjana D. Patel, Esq., delve into the hot sector of eye care, explaining how private equity investment is growing in this field. Read more here .

FDA accepts biologics license application for voretigene neparvovec

An investigational gene therapy candidate for vision loss due to biallelic RPE65-mediated inherited retinal disease (IRD), voretigene neparvovec, which has the proposed trade name of Luxturna, could be both the first gene therapy for a genetic disease in the United States and the first pharmacologic treatment for IRD. Read more here.

Latest LASIK platforms boost patient-reported outcomes

A meta-analysis of FDA patient-reported outcomes showed significant improvement in night vision and driving after LASIK with three of the latest FDA-approved laser platforms. Patient satisfaction was high, and dry eye was mild and transient. Read more here, including peer perspective from Jorge L. Alió, MD, PhD.

NEI highlights advancements for Dry Eye Awareness Month

Recent advancements in dry eye disease research are leading to developments in long-term therapies, according to the National Eye Institute. Read more here.

Diabetes-related retinal ganglion cell loss starts early

Retinal ganglion cell loss due to type 1 diabetes begins in early childhood and is detectable by OCT before any sign of diabetic retinopathy occurs, according to a study. Read more here.